Cambium Oncology

Executive Summary

Cambium Oncology is a preclinical-stage biotechnology company based in Cambridge, MA, founded in 2018. The company is pioneering a novel immunotherapeutic approach that targets the VIP (vasoactive intestinal peptide) signaling pathway, which plays a key role in tumor immune evasion. By disrupting this pathway, Cambium aims to reinvigorate anti-tumor immune responses, offering a potential treatment for multiple cancer types. The company is led by a team of experienced scientists, drug developers, and oncologists, and is currently in the preclinical phase, focusing on lead optimization and IND-enabling studies. With a strong scientific rationale and a differentiated mechanism of action, Cambium represents an early-stage opportunity in the immuno-oncology space. Its progress will depend on successful preclinical validation, partnership development, and securing additional funding to advance toward clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate nomination and advancement to IND-enabling studies60% success
• Q4 2026Series A financing round closing70% success
• TBDPublication of preclinical proof-of-concept data in a peer-reviewed journal50% success